Innovative Trial Offers Hope for Pancreatic Cancer Patients
Innovative Trial Offers Hope for Pancreatic Cancer Patients
Innovative Trial Offers Hope for Pancreatic Cancer Patients
Key Takeaways (TLDR)
Theriva Biologics is leading in developing oncolytic virus therapies for pancreatic cancer, potentially offering a competitive advantage in the treatment of this challenging disease.
Theriva's phase 2b trial with oncolytic virus therapy VCN-01 and chemotherapy drugs aims to improve treatment outcomes for pancreatic cancer patients.
Theriva's work with oncolytic virus therapies has the potential to provide safer and more effective treatment options, offering hope for pancreatic cancer patients and their families.
Theriva Biologics is exploring the use of oncolytic virus therapy VCN-01 for pediatric refractory retinoblastoma and adult ovarian cancer, showing promise in treating various types of cancer.
Why it Matters
The disproportionate rise in pancreatic cancer cases among young women highlights the urgent need for safe and effective treatments. Theriva Biologics' innovative approach with oncolytic virus therapies offers hope for improving outcomes and reducing negative side effects for pancreatic cancer patients.
Summary
In 2023, television personality Maria Menounos acknowledged that she had been diagnosed with pancreatic cancer. Fortunately for Menounos, physicians detected the rare, less aggressive form of the disease when it was still in an early stage. Pancreatic cancer is currently the third leading cause of cancer-related deaths in America, and incidents of pancreatic cancer are increasing, especially among women under 55. The lack of clear symptoms and effective screening methods makes it difficult to detect and treat pancreatic cancer in its early stages.
Theriva Biologics is conducting a phase 2b trial with patients diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) using their lead therapy candidate, VCN-01, in combination with two forms of chemotherapy drugs. The company's innovative approach with oncolytic virus therapies holds promise for improving outcomes and reducing negative side effects in pancreatic cancer patients.
Theriva's work is important due to the high unmet need for safe and effective treatments for pancreatic cancer. The company's efforts could potentially address this need and make a significant impact on the lives of patients with PDAC and other solid cancers.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Innovative Trial Offers Hope for Pancreatic Cancer Patients.